Butyrolactone I

Overview

Butyrolactone I is an orally active and ATP-competitive inhibitor of CDK1 . Butyrolactone I inhibits NF-κB , cdc2 kinase, Bax , ROS production, modulates the PERK/CHOP . Butyrolactone I mitigates heat-stress-induced Apoptosis . Butyrolactone I shows anti-inflammatory and intestinal protective activity. Butyrolactone I has antitumor effects against non-small cell lung, small cell lung, prostate cancer and leukemia. Butyrolactone I can be used in NASH research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-111237
• CAS No.: 87414-49-1
• Molecular Formula: C24H24O7
• Molecular Weight: 424.44
• Purity: 99.80%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution
• Availability: In-stock

Source

Original product source